A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40m.

Trial Profile

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40m.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Rabeprazole (Primary) ; Esomeprazole
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Acronyms TREAT
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 25 Nov 2009 Results presented at GASTRO 2009.
    • 30 May 2009 Results were published in an abstract in the proceedings of the Digestive Disease Week 2009.
    • 26 May 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top